NPI: 1326115569 · LAURIUM, MI 49913 · Critical Access Hospital · NPI assigned 11/30/2006
Authorized official YANG, JERRY controls 20+ related entities in our dataset. Read more
| Authorized Official | YANG, JERRY (SVP & CHIEF FINANCIAL OFFICER) |
| NPI Enumeration Date | 11/30/2006 |
Other providers sharing the same authorized official: YANG, JERRY
| Year | Claims | Total Paid |
|---|---|---|
| 2018 | 25,828 | $619K |
| 2019 | 24,549 | $571K |
| 2020 | 20,086 | $731K |
| 2021 | 23,397 | $1.03M |
| 2022 | 24,188 | $1.03M |
| 2023 | 25,594 | $1.11M |
| 2024 | 20,543 | $943K |
| Code | Description | Claims | Beneficiaries | Total Paid |
|---|---|---|---|---|
| 99284 | Emergency department visit for the evaluation and management, high severity | 7,959 | 5,194 | $1.20M |
| 99283 | Emergency department visit for the evaluation and management, moderate severity | 11,777 | 7,774 | $1.16M |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed | 3,653 | 3,399 | $697K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 6,150 | 4,587 | $518K |
| 99285 | Emergency department visit for the evaluation and management, high severity with immediate threat to life | 1,294 | 1,086 | $361K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 2,260 | 2,025 | $287K |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed | 1,250 | 1,179 | $184K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 1,215 | 653 | $167K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1,184 | 776 | $140K |
| 96375 | Therapeutic injection; each additional sequential IV push | 2,098 | 1,700 | $94K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | 885 | 861 | $92K |
| 71046 | Radiologic examination, chest; 2 views | 2,342 | 1,461 | $75K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 1,052 | 1,011 | $73K |
| 96361 | Intravenous infusion, hydration; each additional hour | 1,636 | 1,413 | $63K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | 2,860 | 862 | $60K |
| 84443 | Thyroid stimulating hormone (TSH) | 5,530 | 5,406 | $52K |
| 70450 | Computed tomography, head or brain; without contrast material | 655 | 438 | $52K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | 2,622 | 2,604 | $50K |
| 71045 | Radiologic examination, chest; single view | 1,767 | 946 | $49K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 1,979 | 1,704 | $46K |
| 80053 | Comprehensive metabolic panel | 11,703 | 10,293 | $44K |
| 80061 | Lipid panel | 3,041 | 2,995 | $40K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 13,625 | 11,835 | $39K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 1,001 | 962 | $36K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 1,416 | 1,395 | $32K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 380 | 192 | $32K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 1,402 | 1,381 | $32K |
| 36415 | Collection of venous blood by venipuncture | 14,765 | 12,377 | $27K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 78 | 78 | $21K |
| 82728 | 2,290 | 2,214 | $19K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 2,409 | 2,201 | $18K |
| 73630 | 1,022 | 520 | $18K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | 382 | 217 | $17K |
| 84439 | 3,111 | 3,069 | $17K | |
| G0145 | Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, with screening by automated system and manual rescreening under physician supervision | 781 | 773 | $13K |
| 83036 | Hemoglobin; glycosylated (A1C) | 1,958 | 1,949 | $12K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 169 | 146 | $10K |
| 86900 | 252 | 221 | $10K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | 612 | 602 | $10K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 284 | 157 | $9K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 361 | 105 | $9K |
| 80306 | 1,737 | 1,586 | $8K | |
| 82607 | 865 | 857 | $8K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | 382 | 368 | $8K |
| 80048 | Basic metabolic panel (calcium, ionized) | 1,673 | 1,547 | $7K |
| 87070 | 1,842 | 1,486 | $7K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 55 | 51 | $7K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | 63 | 62 | $7K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | 314 | 97 | $6K |
| 87086 | Culture, bacterial; quantitative colony count, urine | 1,423 | 1,369 | $6K |
| 73564 | 177 | 92 | $6K | |
| 87088 | 1,193 | 1,038 | $5K | |
| 72100 | 155 | 100 | $4K | |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 12 | 12 | $4K |
| 73030 | 210 | 115 | $4K | |
| 73110 | 215 | 123 | $4K | |
| 86803 | 396 | 392 | $4K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 1,002 | 484 | $3K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | 58 | 36 | $3K |
| 86665 | 179 | 124 | $3K | |
| 83735 | 2,682 | 2,277 | $3K | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | 134 | 133 | $3K |
| 73610 | 189 | 109 | $3K | |
| 86140 | 1,526 | 1,434 | $3K | |
| 73130 | 173 | 113 | $3K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 1,493 | 1,303 | $2K |
| 85610 | 2,001 | 1,585 | $2K | |
| 81001 | 3,802 | 3,456 | $2K | |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | 88 | 88 | $2K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | 67 | 62 | $2K |
| 76801 | 26 | 13 | $2K | |
| 84702 | 171 | 123 | $1K | |
| 86664 | 124 | 124 | $1K | |
| 87077 | 333 | 323 | $1K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | 330 | 328 | $1K |
| 86850 | 372 | 321 | $1K | |
| 86663 | 124 | 124 | $1K | |
| 86376 | 130 | 126 | $1K | |
| 83690 | 1,394 | 1,267 | $933.22 | |
| 87186 | 225 | 220 | $892.50 | |
| 83540 | 197 | 194 | $811.20 | |
| 84481 | 90 | 85 | $804.06 | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | 12 | 12 | $640.86 |
| 85652 | 492 | 461 | $620.16 | |
| 83550 | 102 | 100 | $590.96 | |
| 82746 | 76 | 72 | $540.19 | |
| 88342 | 24 | 12 | $539.18 | |
| 85027 | 117 | 112 | $431.88 | |
| 84153 | 36 | 36 | $429.49 | |
| 94762 | 29 | 28 | $398.99 | |
| 86769 | 15 | 15 | $393.45 | |
| 73502 | 14 | 13 | $347.49 | |
| 84484 | 1,384 | 1,035 | $309.64 | |
| G0328 | Colorectal cancer screening; fecal occult blood test, immunoassay, 1-3 simultaneous | 28 | 27 | $275.12 |
| 84425 | 24 | 21 | $237.62 | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 1,073 | 1,037 | $235.06 |
| 86762 | 25 | 25 | $223.42 | |
| 81025 | 640 | 612 | $221.26 | |
| 83880 | 24 | 24 | $206.96 | |
| 85730 | 440 | 421 | $199.91 | |
| 86592 | 70 | 67 | $197.42 | |
| 86800 | 26 | 25 | $184.80 | |
| 82533 | 15 | 13 | $183.89 | |
| 87340 | 25 | 25 | $160.39 | |
| 83090 | 20 | 17 | $151.12 | |
| 82043 | 43 | 43 | $145.64 | |
| 87807 | 39 | 39 | $136.88 | |
| 82948 | 225 | 183 | $135.73 | |
| 87205 | 58 | 57 | $125.61 | |
| 85379 | 108 | 106 | $92.42 | |
| 82180 | 12 | 12 | $89.52 | |
| 83605 | 362 | 297 | $65.04 | |
| 84703 | 182 | 173 | $58.96 | |
| 82570 | 18 | 16 | $49.66 | |
| 82248 | 43 | 37 | $32.34 | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | 242 | 173 | $29.60 |
| 82550 | 14 | 14 | $5.23 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | 2,275 | 1,811 | $3.88 |
| 94760 | 78 | 65 | $0.00 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | 1,074 | 791 | $0.00 |
| 86901 | 262 | 221 | $0.00 | |
| J2704 | Injection, propofol, 10 mg | 978 | 856 | $0.00 |
| J1170 | Injection, hydromorphone, up to 4 mg | 153 | 113 | $0.00 |
| G0378 | Hospital observation service, per hour | 27 | 25 | $0.00 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | 40 | 37 | $0.00 |
| 82962 | 66 | 63 | $0.00 | |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | 39 | 34 | $0.00 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | 88 | 84 | $0.00 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | 62 | 58 | $0.00 |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 1,919 | 1,361 | $0.00 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | 2,012 | 1,663 | $0.00 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | 175 | 128 | $0.00 |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | 24 | 24 | $0.00 |
| 81291 | 12 | 12 | $0.00 | |
| S0119 | Ondansetron, oral, 4 mg (for circumstances falling under the medicare statute, use hcpcs q code) | 12 | 12 | $0.00 |